Annual Cash & Cash Equivalents
$75.00 M
+$6.57 M+9.60%
31 December 2023
Summary:
Adverum Biotechnologies annual cash & cash equivalents is currently $75.00 million, with the most recent change of +$6.57 million (+9.60%) on 31 December 2023. During the last 3 years, it has risen by +$12.58 million (+20.15%). ADVM annual cash & cash equivalents is now -66.24% below its all-time high of $222.17 million, reached on 31 December 2016.ADVM Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Cash And Cash Equivalents
$92.85 M
-$34.47 M-27.07%
30 September 2024
Summary:
Adverum Biotechnologies quarterly cash and cash equivalents is currently $92.85 million, with the most recent change of -$34.47 million (-27.07%) on 30 September 2024. Over the past year, it has dropped by -$12.52 million (-11.88%). ADVM quarterly cash and cash equivalents is now -62.42% below its all-time high of $247.08 million, reached on 31 March 2016.ADVM Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
ADVM Cash And Cash Equivalents Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +9.6% | -11.9% |
| 3 y3 years | +20.1% | +181.6% |
| 5 y5 years | -51.6% | +26.9% |
ADVM Cash And Cash Equivalents High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | at high | +119.3% | -37.9% | +181.6% |
| 5 y | 5 years | -51.6% | +119.3% | -37.9% | +239.4% |
| alltime | all time | -66.2% | >+9999.0% | -62.4% | >+9999.0% |
Adverum Biotechnologies Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $92.85 M(-27.1%) |
| June 2024 | - | $127.32 M(-14.9%) |
| Mar 2024 | - | $149.61 M(+99.5%) |
| Dec 2023 | $75.00 M(+9.6%) | $75.00 M(-28.8%) |
| Sept 2023 | - | $105.37 M(-5.2%) |
| June 2023 | - | $111.19 M(+64.6%) |
| Mar 2023 | - | $67.55 M(-1.3%) |
| Dec 2022 | $68.43 M(+100.1%) | $68.43 M(-18.9%) |
| Sept 2022 | - | $84.43 M(-8.1%) |
| June 2022 | - | $91.87 M(+2.5%) |
| Mar 2022 | - | $89.65 M(+162.2%) |
| Dec 2021 | $34.20 M(-45.2%) | $34.20 M(+3.7%) |
| Sept 2021 | - | $32.97 M(-30.3%) |
| June 2021 | - | $47.30 M(+4.1%) |
| Mar 2021 | - | $45.42 M(-27.2%) |
| Dec 2020 | $62.42 M(-5.3%) | $62.42 M(-14.1%) |
| Sept 2020 | - | $72.70 M(+165.7%) |
| June 2020 | - | $27.36 M(-79.0%) |
| Mar 2020 | - | $130.16 M(+97.5%) |
| Dec 2019 | $65.90 M | $65.90 M(-9.9%) |
| Sept 2019 | - | $73.17 M(-25.2%) |
| June 2019 | - | $97.81 M(-32.1%) |
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2019 | - | $144.11 M(-7.0%) |
| Dec 2018 | $154.95 M(+119.7%) | $154.95 M(-3.0%) |
| Sept 2018 | - | $159.67 M(+2.7%) |
| June 2018 | - | $155.45 M(+1.8%) |
| Mar 2018 | - | $152.72 M(+116.6%) |
| Dec 2017 | $70.52 M(-68.3%) | $70.52 M(+122.4%) |
| Sept 2017 | - | $31.71 M(-19.8%) |
| June 2017 | - | $39.52 M(-44.8%) |
| Mar 2017 | - | $71.57 M(-67.8%) |
| Dec 2016 | $222.17 M(+0.4%) | $222.17 M(-3.9%) |
| Sept 2016 | - | $231.27 M(-4.2%) |
| June 2016 | - | $241.30 M(-2.3%) |
| Mar 2016 | - | $247.08 M(+11.6%) |
| Dec 2015 | $221.35 M(+38.9%) | $221.35 M(+10.3%) |
| Sept 2015 | - | $200.68 M(+0.1%) |
| June 2015 | - | $200.54 M(-0.6%) |
| Mar 2015 | - | $201.85 M(+26.6%) |
| Dec 2014 | $159.40 M(>+9900.0%) | $159.40 M(-3.6%) |
| Sept 2014 | - | $165.33 M(+215.3%) |
| June 2014 | - | $52.43 M(+3.5%) |
| Mar 2014 | - | $50.68 M(+8885.6%) |
| Dec 2013 | $564.00 K(+58.0%) | $564.00 K |
| Dec 2012 | $357.00 K | - |
FAQ
- What is Adverum Biotechnologies annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Adverum Biotechnologies?
- What is Adverum Biotechnologies annual cash & cash equivalents year-on-year change?
- What is Adverum Biotechnologies quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for Adverum Biotechnologies?
- What is Adverum Biotechnologies quarterly cash and cash equivalents year-on-year change?
What is Adverum Biotechnologies annual cash & cash equivalents?
The current annual cash & cash equivalents of ADVM is $75.00 M
What is the all time high annual cash & cash equivalents for Adverum Biotechnologies?
Adverum Biotechnologies all-time high annual cash & cash equivalents is $222.17 M
What is Adverum Biotechnologies annual cash & cash equivalents year-on-year change?
Over the past year, ADVM annual cash & cash equivalents has changed by +$6.57 M (+9.60%)
What is Adverum Biotechnologies quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of ADVM is $92.85 M
What is the all time high quarterly cash and cash equivalents for Adverum Biotechnologies?
Adverum Biotechnologies all-time high quarterly cash and cash equivalents is $247.08 M
What is Adverum Biotechnologies quarterly cash and cash equivalents year-on-year change?
Over the past year, ADVM quarterly cash and cash equivalents has changed by -$12.52 M (-11.88%)